Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association Between Early Initiation of Electroconvulsive Therapy and Length of Stay in Acute Psychiatric Inpatients: A Retrospective Cohort Study in Taiwan.

The journal of ECT·2026
Same author

First-in-human application of robotic vascularized intercostal nerve grafts for thoracic sympathetic trunk reconstruction: a technical innovation.

BMC surgery·2025
Same author

The history and development of sympathetic trunk reconstruction: a 40-year journey from open surgery to robotic-assisted microsurgery.

Journal of robotic surgery·2025
Same author

Robotic sympathetic trunk reconstruction for compensatory sweating after thoracic sympathectomy.

JTCVS techniques·2023
Same author

Temporal reciprocal relationships among anxiety, depression, and posttraumatic stress disorder for family surrogates from intensive care units over their first two bereavement years.

BMC psychiatry·2023
Same author

Effectiveness of aftercare program for suicide ideators: Real-world evidence from National Suicide Surveillance System in Taiwan.

Medicine·2022

Related Experiment Video

Updated: May 11, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.

Chin-Pang Lee, Alice Pei-Jung Chen, Yeong-Yuh Juang

    Clinical Schizophrenia & Related Psychoses
    |May 7, 2013
    PubMed
    Summary

    Switching to ziprasidone, a second-generation antipsychotic (SGA), unexpectedly caused weight gain and metabolic syndrome (MetS) in a schizophrenia patient. This contrasts with ziprasidone

    Area of Science:

    • Pharmacology
    • Metabolic Disorders
    • Psychiatry

    Background:

    Keywords:
    PolypharmacySchizophreniaWeight GainZiprasidone

    More Related Videos

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity
    03:37

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity

    Published on: June 8, 2021

    Related Experiment Videos

    Last Updated: May 11, 2026

    Multidisciplinary Approach to Obesity Management: A Case Report
    05:10

    Multidisciplinary Approach to Obesity Management: A Case Report

    Published on: May 30, 2025

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity
    03:37

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity

    Published on: June 8, 2021

    • Second-generation antipsychotics (SGAs), valproate, and sulpiride are linked to significant weight gain and metabolic syndrome (MetS) risk.
    • Olanzapine and clozapine (SGAs) pose the highest metabolic risks, while ziprasidone is associated with the lowest.
    • Previous reports indicate weight loss when switching to ziprasidone from other antipsychotics.